Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.90 |
| ▸ | MAOA | P21397 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 3/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CDC25B | P30305 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.52 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 6/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408351 | 1.00 | CES1 (0.90) | CES1MAOAL3MBTL1TDP1MAOB | |
| SCHEMBL44496 | 1.00 | CES1 (0.90) | CES1MAOAL3MBTL1TDP1MAOB | |
| SCHEMBL13712393 | 0.94 | CES1 (1.00) | CES1MAOAL3MBTL1TDP1MAOB | |
| SCHEMBL11144928 | 0.90 | CES1 (0.73) | CES1MAOAL3MBTL1TDP1MAOB | |
| SCHEMBL29384891 | 0.87 | CES1 (0.77) | CES1MAOAL3MBTL1TDP1MAOB | |
| SCHEMBL2231281 | 0.87 | CES1 (0.77) | CES1MAOAL3MBTL1TDP1MAOB | |
| SCHEMBL1739155 | 0.84 | CES1 (0.71) | CES1MAOAL3MBTL1TDP1MAOB | |
| SCHEMBL5508289 | 0.84 | CES1 (0.71) | CES1MAOAL3MBTL1TDP1MAOB | |
| Anthrone SCHEMBL18143 | 0.83 | MAOA (1.00) | CES1MAOAL3MBTL1TDP1MAOB | |
| Anthrone SCHEMBL29357010 | 0.83 | MAOA (1.00) | CES1MAOAL3MBTL1TDP1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692092-A1 | NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF | Aliad Biopharma (KR) | 2026-02-11 | — | — | EP | disclosed |
| CN-120025250-A | Synthesis method of cyclobenzaprine hydrochloride | 山东新时代药业有限公司 | 2025-05-23 | — | — | CN | disclosed |
| WO-2025104433-A1 | CATALYST AND SYNTHESIS THEREOF | UNIVERSITY OF STRATHCLYDE (GB) | 2025-05-22 | — | — | WO | disclosed |
| WO-2024205377-A1 | NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF | 알리아드바이오파마 주식회사 | 2024-10-03 | — | — | WO | disclosed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | CES1 4476/4885MAOA 3791/4885L3MBTL1 421/4885 |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | CES1 4476/4885MAOA 3791/4885L3MBTL1 421/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | CES1 4476/4885MAOA 3791/4885L3MBTL1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.